Navigation Links
Mach One Corporation Files its Form SB-2 with the SEC
Date:10/16/2007

LAS VEGAS, Oct. 16 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN) is proud to announce that it has filed its SB-2 registration with the Securities and Exchange Commission. The company had announced previously its intention of becoming a fully reporting company under the 1934 Act, and today made it official. The company is next filing to be listed on the OTCBB following the effectiveness of the SB-2. "This is a monumental day for Mach One; we are now poised to move forward as fully reporting company with the next step -- the OTCBB," said Monte Tobin, CEO of Mach One. "Upon the effectiveness of the registration, we will make a public announcement for the benefit of our shareholders and future shareholders.

Mach One Corporation is currently trading on the Pink Sheets, under the symbol MNCN. Upon the effective date of the filing, the Company will attain Section 12 (g) reporting status with the SEC, under the Exchange Act of 1934, which will allow for broader market participation in the Company's shares by institutional investors. As a reporting company, Mach One Corporation will be required to file annual reports on Form 10-KSB, quarterly reports on Form 10-QSB, and reports of unusual events on Form 8K. In addition, the Company will be required to solicit proxies for its annual meetings in accordance to Section 14 of the Securities Exchange Act of 1934 and other reporting requirements will apply to management shareholdings.

Investors can view the filing by accessing the SEC's website at http://www.sec.gov.

About Mach One Corporation

The company (http://www.machonecorp.com) specializes in Immune or Gamma Globulin replacement (IgG) for the equine and bovine markets. Through it's subsidiary company VDx, Inc., the company plans full scale manufacturing and distribution of Immunogam(TM), a colostrums replacement, supplement and prophylactic, in sterile powder form, that can be administered orally or intravenously. VDx is also further developing a proprietary procedure to allow for large scale manufacturing of colostral replacement products for market along with an added ingredient for the elimination of Mastitis and Johnnes disease.

Cautionary Statement: This news release may include certain "Forward- looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.


'/>"/>
SOURCE Mach One Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
2. Novartis files application with FDA for Zometa
3. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
4. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
5. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
6. Personality profiles of gamblers and substance abusers are similar
7. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
8. Venus Remedies Files 5th International Patent Application
9. Shoaib Akhtar files appeal against ban
10. AIIMS Official Files Complaint Against Venugopal
11. Glaxo Files Cancer Drug For Approval With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: